PCN65 THE CHALLENGE OF VALUE-BASED PRICING IN COMBINATION THERAPY:THE CASE OF TRASTUZUMAB AND PERTUZUMAB IN HER2+ METASTATIC BREAST CANCER.

Under current reimbursement (CR) practice, although an add-on medicine in a combination therapy may produce marginal value in terms of health gain, the original therapy may also share in the reward for this additional value. Our aim was to evaluate the impact of MVBR model on effective price (EP) and value-based price (VBP) of an add-on therapy, as compared to CR model. Conclusions If pertuzumab as the add-on therapy in combination were to fully capture the marginal value, its EP and VBP would be significantly higher compared to those prices under the CR model. [Extracted from the article]